Abgent (WuXi AppTec) specializes in the development and production of high-quality antibodies and peptides, catering to a wide range of research areas including cancer, metabolism, cardiovascular health, neuroscience, and stem cell research. Their offerings include custom antibody development services, which encompass both monoclonal and polyclonal antibody production, as well as anti-drug antibody services. The company emphasizes the quality of its products through rigorous validation processes, including lot-to-lot testing and the use of state-of-the-art equipment to ensure that their antibodies are effective in biologically relevant applications. Additionally, Abgent provides a comprehensive catalog of peptides, including a specific collection derived from the SARS-CoV-2 viral genome, which aids researchers in studying immune responses and vaccine development.

In addition to their product offerings, Abgent supports researchers with extensive technical assistance and resources. They provide standard protocols for various applications such as Western blotting, immunohistochemistry, and flow cytometry, ensuring that users can effectively utilize their products. The company also maintains a technical support ticket system for inquiries, allowing for efficient communication and resolution of issues. With a commitment to innovation, Abgent develops over 1,000 new products annually, focusing on both established and novel targets, and collaborates with experts to enhance their antibody development processes. This dedication to quality and customer support positions Abgent as a valuable partner in the scientific community.

United States

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

Abgent (WuXi AppTec)

Company Details